Possibilities of spectrometric diagnostics of benign and malignant conjunctival tumors
https://doi.org/10.21516/2072-0076-2023-16-2-119-123
Abstract
Purpose: to compare the regenerative activity of benign and malignant conjunctival tumors.
Material and methods. The study was performed on 86 tumor biopsies from patients with a clinically diagnosed conjunctival neoplasm. Healthy tissues from the same eye were taken as a control sample. The optical density of the reaction mixture containing biogenic nanoparticles formed in the presence of conjunctival tumors and the corresponding paired healthy tissue samples from the control group was measured by spectrophotometry. The data obtained were later verified by a pathohistological analysis.
Results. A significantly higher level of in situ formation of biogenic silver nanoparticles was recorded in the reaction mixture with malignant tumors of the conjunctiva (3.0 ± 1.1, (n = 32) compared to benign tumors (1.3 ± 0.2, n = 54). No differences were found between various types of benign tumors. In samples of malignant tumors, the indicators of recovery activity in melanoma (3.4 ± 1.0, n = 14) and lymphoma (2.8 ± 1.0, n = 7) were significantly higher than in squamous cell carcinoma (2.0 ± 0.6, n = 11), but no significant differences were found between the two types of tumors.
Conclusion. The method of spectrophotometric measurement of the regenerative activity of conjunctival tumors can be used in preoperative or intraoperative diagnostics thanks to the fact that the results can be obtained rapidly, which will help to quickly determine the extent of surgical intervention needed and optimize the treatment tactics.
About the Authors
S. V. Saakyan
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Svetlana V. Saakyan, corresponding member of RAS, Dr. of Med. Sci., professor, corresponding member of the Russian Academy of Sciences, head of department of ocular oncology and radiology,
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
D. A. Skladnev
Research Center of Biotechnology, S.N.Vinogradsky Institute of Microbiology, RAS
Russian Federation
Russian Federation
Dmitry A. Skladnev, Dr. of Biol. Sci., professor, chief researcher, microbial survival laboratory,
33/2, Leninsky Prospekt, Moscow, 119071
A. P. Alekseeva
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Alena P. Alekseeva, PhD student, department of ocular oncology and radiology,
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
V. V. Sorokin
Research Center of Biotechnology, S.N.Vinogradsky Institute of Microbiology, RAS
Russian Federation
Russian Federation
Vladimir V. Sorokin, senior researcher, microbial survival laboratory,
33/2, Leninsky Prospekt, Moscow, 119071
O. V. Beznos
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Olga V. Beznos, physician of department of pathophysiology and biochemistry,
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
References
1. Brovkina A.F. Ophthalmooncology. Guidelines for physicians. Moscow: Meditsina; 2002 (In Russ.).
2. Brovkina A.F. Clinical features of malignant orbital lymphoma. Vestnik Oftal’mologii. 2019; 135 (5): 4–12 (In Russ.). doi: 10.17116/oftalma20191350514
3. Saakyan S.V. Clinical oncology of visual organ. Effective pharmacotherapy. 2015; 30: 20–7 (in Russ.).
4. Semenova L.E., Panova I.E., Musaeva P.I. Clinical and epidemiological aspect of malignant neoplasm of conjunctiva in the Chelyabinsk region. Russian ophthalmological journal. 2020; 13 (4): 33–8 (In Russ.). https://doi.org/10.21516/2072-0076-2020-13-4-33-38
5. Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Indian J Ophthalmol. 2019; 67 (12): 1930–48. doi: 10.4103/ijo.IJO_2040_19
6. Engibarjan M.A. To the question on eye recurrent malignant tumours. Kubansky nauchnomeditsinsky vestnik. 2011; 1 (124): 116–8 (In Russ.).
7. Grossniklaus HE, Eberhart CG, Kivel TT. WHO classification of tumours. 2018; 4th ed. vol. 12.
8. Korshunov D.A., Kondakova I.V., Shashova E.E. Modern perspective on metabolic reprogramming in malignant neoplasms. Biochemistry. 2019; 84 (10): 1129–42 (In Russ.). doi: 10.1134/S0320972519100026
9. De Berardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016; 2 (5): e1600200. doi: 10.1126/sciadv.1600200
10. Hanahan D. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646–74. doi: 10.1016/j.cell.2011.02.013
11. Mart nez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021. 21: 669–80. doi: 10.1038/s41568-021-00378-6
12. Gao S, Chen D, Li Q, et al. Near-infrared fluorescence imaging of cancer cells and tumors through specific biosynthesis of silver nanoclusters. Scientific Reports. 2014; 4: 4384. https://doi.org/10.1038/srep04384
13. Pandey N, Lanke V, Vinod PK. Network-based metabolic characterization of renal cell carcinoma. Sci Rep. 2020; 10: 5955. https://doi.org/10.1038/s41598- 020-62853-8
14. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim Biophys Acta. 2011; 1807 (6): 552–61. doi: 10.1016/j.bbabio.2010.10.012
15. Kang HS, Lee SC, Park YS, et al. Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype. BMC Cancer. 2011; 11: 465. doi: 10.1016/j.bbabio.2010.10.012
Review
For citations:
Saakyan S.V., Skladnev D.A., Alekseeva A.P., Sorokin V.V., Beznos O.V. Possibilities of spectrometric diagnostics of benign and malignant conjunctival tumors. Russian Ophthalmological Journal. 2023;16(2):119-123. (In Russ.) https://doi.org/10.21516/2072-0076-2023-16-2-119-123
Views:
430
Email this article 